Therapeutic agent for hepatitis C
US9006285B2 · kind B2 · utility
91Cited by
0References
17Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 30, 2009 |
| Grant date | Apr 14, 2015 |
| Priority date | — |
| Expiry date | Mar 24, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a novel therapeutic means against interferon-resistant hepatitis C. Specifically disclosed are: a pharmaceutical composition for treating interferon-resistant hepatitis C, which is characterized by comprising at least one component selected from the group consisting of an ω-3 polyunsaturated fatty acid, a pharmaceutically acceptable salt of the fatty acid and an ester of the fatty acid as an active ingredient; and a method for utilizing the pharmaceutical composition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.